Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen- and estrogen-receptor independent mechanism

FEBS Journal

Volumn 276, Issue 19, 2009, Pages 5598-5609

  Girón, Roma A ^a   Montaño, Luis F ^b   Escobar, María L ^c   López Marure, Rebeca ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Androgen receptor; Cell proliferation; DHEA; Estrogen receptor; HPV

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 2,5 DIPHENYL TETRAZOLIUM BROMIDE; ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; FLUTAMIDE; FULVESTRANT; LETROZOLE; PRASTERONE; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DEHYDROEPIANDROSTERONE; FEMALE; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; NECROSIS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 70349235700     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07253.x     Document Type: Article

References (57)

1. Hayashi T, Esaki T, Muto E, Kano H, Asai Y, Thakur NK, Sumi D, Jayachandran M Iguchi A (2000) Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol 20, 782 792.
2. Williams MR, Ling S, Dawood T, Hashimura K, Dai A, Li H, Liu JP, Funder JW, Sudhir K Komesaroff PA (2002) Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of Ars and Ers. J Clin Endocrinol Metab 87, 176 181.
3. Gayosso V, Montaño LF López-Marure R (2006) DHEA-induced antiproliferative effect in MCF-7 cells is androgen- and estrogen receptor independent. Cancer J 12, 160 165.
4. Liu D, Iruthayanathan M, Homan LL, Wang Y, Yang L, Wang Y Dillon JS (2008) Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms. Endocrinology 149, 889 898.
5. Regelson W, Kalimi M Loria M (1990) DHEA: some thoughts as to its biological and clinical action. In The Biologic Role of Dehydroepiandrosterone (DHEA) (Kalimi M Regelson W eds pp. 405 445. Walter de Gruyter & Co, New York.
6. Eich DM, Nestler JE, Johnson DE, Wechsler AS Hess ML (1993) Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 8, 261 269.
7. Schwartz AG, Pashko L Whitcomb JM (1986) Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol 14, 357 362.
8. Gutiérrez G, Mendoza C, Zapata E, Montiel A, Reyes E, Montaño LF López-Marure R (2007) Dehydroepiandrosterone inhibits the TNF-alpha-induced inflammatory response in human umbilical vein endothelial cells. Atherosclerosis 190, 90 99.
9. López-Marure R, Huesca-Gómez C, Ibarra-Sánchez Mde J, Zentella A Pérez-Méndez O (2007) Dehydroepiandrosterone delays LDL oxidation in vitro and attenuates several oxLDL-induced inflammatory responses in endothelial cells. Inflamm Allergy Drug Targets 6, 174 182.
10. Simile M, Pascale RM, De Miglio MR, Nufris A, Daino L, Seddaiu MA, Muroni MR, Rao KN Feo F (1995) Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis. Int J Cancer 62, 210 215.
11. Osawa E, Nakajima A, Yoshida S, Omura M, Nagase H, Ueno N, Wada K, Matsuhashi N, Ochiai M, Nakagama H et al. (2002) Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). Life Sci 70, 2623 2630.
12. Moore M, Thamavit W, Tsuda H, Sato K, Ichihara A Ito N (1986) Modifying influence of dehydroepiandrosterone on the development of dihydroxy-di-n- propylnitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis 7, 311 316.
13. Pashko L, Hard G, Rovito R, Williams J, Sobel E Schwartz A (1985) Inibition of 7,12-dimethylbenz(a)anthracene-induced skin papillomas and carcinomas by dehydroepiandrosterone and 3-β-methylandrost-5-en-17-one in mice. Cancer Res 45, 164 166.
14. Schwartz A Pashko L (1995) Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Suppl 22, 210 217.
15. McCormick DL, Rao KV, Johnson WD, Bowman-Gram TA, Steele VE, Lubet RA Kellof GJ (1996) Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. Cancer Res 56, 1724 1726.
16. Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE, Kelloff GJ McCormick DL (1999) Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 59, 3084 3089.
17. Schwartz A (1979) Inhibition of spontaneous breast cancer formation in female C3H(Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 39, 1129 1132. (Pubitemid 9135147)
18. Hursting S, Perkins S, Haines D, Ward J Phang J (1995) Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res 55, 3949 3953.
19. Rao A (1989) Inhibitory action of dehydroepiandrosterone on methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse. Cancer Lett 45, 1 5.
20. Suh-Burgmann E, Sivret J, Duska L, Del Carmen M Seiden M (2003) Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study. Gynecol Obstet Invest 55, 25 31.
21. Parkin DM, Bray F, Ferlay J Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94, 153 156. (Pubitemid 32911406)
22. García-López P, Rodríguez-Dorantes M, Pérez-Cárdenas E, Cerbón M Mohar-Betancourt A (2004) Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines. Cancer Chemother Pharmacol 53, 533 540.
23. Solano ME, Sander V, Wald MR Motta AB (2008) Dehydroepiandrosterone and metformin regulate proliferation of murine T lymphocytes. Clin Exp Immunol 153, 289 296.
24. Zapata E, Ventura JL, De la Cruz K, Rodriguez E, Damián P, Massó F, Montaño LF López-Marure R (2005) Dehydroepiandrosterone inhibits the proliferation of HUVEC by enhancing the expression of p53 and p21, restricting the phosphorylation of RB, and is androgen- and estrogen-receptor independent. FEBS J 272, 1343 1353.
25. Gil-ad I, Shtaif B, Eshet R, Maayan R, Rehavi M Weizman A (2001) Effect of dehydroepiandrosterone and its sulfate metabolite on neuronal cell viability in culture. Isr Med Assoc J 3, 639 643.
26. Jiang YF, Zhao PW, Tan Y, Liu LH, Li MH, Matsuzaki Y Niu JQ (2007) Molecular mechanisms of DHEA and DHEAs on apoptosis and cell cycle arrest via Akt pathway in hepatoma cell lines. Zhonghua Gan Zang Bing Za Zhi 15, 441 444.
27. Macville M, Schröck E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, Popescu N Ried T (1999) Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res 59, 141 150.
28. 1 phase which can be substituted for mutations in p53. Oncogene 11, 653 661.
29. Crook T, Wrede D Vousden KH (1991) p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6, 873 875.
30. Mantovani F Banks L (1999) Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene 18, 3309 3315.
31. Shilkaitis A, Green A, Punj V, Steele V, Lubet R Christov K (2005) Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Res 7, R1132 R1140.
32. Akerman GS, Tolleson WH, Brown KL, Zyzak LL, Mourateva E, Engin TS, Basaraba A, Coker AL, Creek KE Pirisi L (2001) Human HPV type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res 61, 3837 3843.
33. Costa S, Terzano P, Santini D, Ceccarelli C, Martoni A, Angelelli B, Panetta A, Bovicelli A, Cristiani P, Lipponen P et al. (2001) Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 116, 729 737.
34. López-Marure R, Gutiérrez G, Mendoza C, Ventura JL, Sánchez L, Reyes Maldonado E, Zentella A Montaño LF (2002) Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. Biochem Biophys Res Commun 293, 1028 1036.
35. Cheng YX, Pu DM, Liu R, Li T, Yin L Ma D (2007) Influence of hypoxia inducible factor-1alpha on cervical cancer cell line HeLa in vitro. Zhonghua Fu Chan Ke Za Zhi 42, 551 554.
36. Dessouroux A, Akwa Y Baulieu EE (2008) DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension. J Steroid Biochem Mol Biol 109, 81 89.
37. Nair HB, Luthra R, Kirma N, Liu YG, Flowers L, Evans D Tekmal RR (2005) Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Res 65, 11164 11173.
38. Labrie F, Belanger A, Labrie C, Simard J, Cusan L, Gomez JL Candas B (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 63, 322 328.
39. Lu SF, Mo Q, Hu S, Garippa C Simon NG (2003) Dehydroepiandrosterone upregulates neural androgen receptor level and transcripcional activity. J Neurobiol 57, 163 171.
40. Martin C, Ross M, Chapman KE, Andrew R, Bollina P, Seckl JR Habib FK (2004) CYP7B generates a selective estrogen receptor β agonist in human prostate. J Clin Endocrinol Metab 89, 2928 2935.
41. Arnold JT Blackman MR (2005) Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer? Endocrinology 146, 4565 4567.
42. Chen F, Knecht K, Birzin E, Fisher J, Wilkinson H, Mojena M, Moreno CT, Schmidt A, Harada S, Freedman LP et al. (2005) Direct agonist/antagonist functions of dehydroepiandrosterone. Endocrinology 146, 4568 4576.
43. Kaufman FR, Stanczyk FZ, Matteri RK, Gentzschein E, Delgado C Lobo RA (1990) Dehydroepiandrosterone and dehydroepiandrosterone sulfate metabolism in human genital skin. Fertil Steril 54, 251 254.
44. Poulin R Labrie F (1986) Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46, 4933 4937.
45. Hähnel R, Martin JD, Masters AM, Ratajczak T Twaddle E (1979) Estrogen receptors and blood hormone levels in cervical carcinoma and other gynecological tumors. Gynecol Oncol 8, 226 233.
46. Vargas Roig LM, Lotfi H, Olcese JE, Lo Castro G Ciocca DR (1993) Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res 13, 2457 2463.
47. Ruutu M, Wahlroos N, Syrjänen K, Johansson B Syrjänen S (2006) Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer 16, 1261 1268.
48. Di Monaco M, Pizzini A, Gatto V, Leonardi L, Gallo M, Brignardello E Boccuzzi G (1997) Role of glucose-6-phosphate dehydrogenase inhibition in the antiproliferative effects of dehydroepiandrosterone on human breast cancer cells. Br J Cancer 75, 589 592.
49. Maggiolini M, Donze O, Jeannin E, Ando S Picard D (1999) Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha. Cancer Res 59, 4864 4869.
50. Schmitt M, Klinga K, Schnarr B, Morfin R Mayer D (2001) Dehydroepiandrosterone stimulates proliferation and gene expression in MCF-7 cells after conversion to estradiol. Mol Cell Endocrinol 173, 1 13.
51. Serrano ML, Sanchez-Gomez M, Bravo MM, Yakar S LeRoith D (2008) Differential expression of IGF-1 and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm Metab Res 40, 661 667.
52. Liu D Dillon JS (2002) Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277, 21379 21388.
53. Leskiewicz M, Jantas D, Budziszewska B Lason W (2008) Excitatory neurosteroids attenuate apoptotic and excitotoxic cell death in primary cortical neurons. J Physiol Pharmacol 59, 457 475.
54. Cheng H, Hu X Ruan Q (2009) Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen. Acta Pharmacol Sin 30, 42 53.
55. Banerjee NS, Genovese NJ, Noya F, Chien WM, Broker TR Chow LT (2006) Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes. J Virol 80, 6517 6524.
56. Yang NC, Jeng KC, Ho WM, Chou SJ Hu ML (2000) DHEA inhibits cell growth and induces apoptosis in BV-2 cells and the effects are inversely associated with glucose concentration in the medium. J Steroid Biochem Mol Biol 75, 159 166.
57. Jiang Y, Miyazaki T, Honda A, Hirayama T, Yoshida S, Tanaka N Matsuzaki Y (2005) Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone. J Gastroenterol 40, 490 497.